Trial
NCT05198349
First in Human Study of M1069 in Advanced Solid Tumors
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Metastatic or Locally Advanced Unresectable Solid Tumors
Intervention
M1069
Why stopped
Overarching portfolio-level review of the company's oncology pipeline resulted in early termination of the study. The study was not terminated due to safety.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-22